key: cord-1025096-ddl6844h
authors: Colavita, F.; Vairo, F.; Meschi, S.; Valli, B.; Lalle, E.; Castilletti, C.; Fusco, D.; Spiga, G.; Bartoletti, P.; Ursino, S.; Sanguinetti, M.; Di Caro, A.; Vaia, F.; Ippolito, G.; Capobianchi, M. R.
title: COVID-19 Antigen Rapid Test as Screening Strategy at the Points-of-Entry: Experience in Lazio Region, Central Italy, August-October 2020.
date: 2020-11-30
journal: nan
DOI: 10.1101/2020.11.26.20232728
sha: 1d08d9c5593017905113ae4a3a70179a33712f1e
doc_id: 1025096
cord_uid: ddl6844h

COVID-19 pandemic is becoming one of the most dramatic health, social and economic global challenges in recent history. Testing is one of the main components of the public health response to contain the virus spreading. There is an urgent need to expand testing capacity and antigen rapid tests (Ag RDT) represent good candidates for point-of-care and mass surveillance testing to rapidly identify people with SARS-CoV-2 infection, counterbalancing lower sensitivity as compared to the gold standard molecular tests with timeliness of results and possibility of recurred testing. Here, we report preliminary data of the testing algorithm implemented at the points-of-entry (airports and port) in Lazio Region (Central Italy) on travelers arriving between 17th of August to 15th of October, 2020, using the STANDARD F COVID-19 Antigen Fluorescence ImmunoAssay. Our findings show that the probability of molecular confirmation of Ag RDT positive results is directly dependent from the semi-quantitative results of this Ag RDT, and that the molecularly confirmed samples actually harbor infectious virus. These results support the public health strategies based on early screening campaigns in settings where molecular testing is not feasible or easily accessible, using rapid and simple point of care tests, able to rapidly identify those subjects who are at highest risk of spreading SARS-CoV-2 infection.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.26.20232728 doi: medRxiv preprint

As of November 15 th , 2020, COVID-19 pandemic continues to spread worldwide accounting for a total of over 53,766,728 cases and 1,308,975 deaths, with high impact on healthcare systems and devastating global socio-economic consequences [1] . With COVID-19 cases accelerating towards a second wave for many Countries and a further overburden on health care systems and laboratories, there is an urgent need to expand testing capacity, in order to quickly identify as many SARS-CoV-2 positive persons as possible to control infection transmission [2] [3] [4] .

Nucleic acid amplification test (NAAT) is the gold standard for the diagnosis of SARS-CoV-2 infection, however it is laborious, expensive, and challenged by reagent supply shortage [4] [5] [6] .

Antigen rapid tests (Ag RDT) can represent a good option for mass testing and for rapidly capturing individuals potentially more infectious, especially in decentralized settings, or in those scenarios where molecular testing is not feasible or easily accessible. In fact, despite the lower sensitivity, they are able to identify current infections during the most contagious phase and are faster, simpler-to-use, and less expensive than NAAT [7] [8] . Overall, these tests may ultimately help to relieve the pressure on healthcare systems. The variability of the clinical performance is one of the limiting factors of Ag RDT [7; 9], however their use may be of a greater benefit if compared to the risks associated with no testing, especially for effective and sustainable surveillance regimens [3; 10]. The global request for 'test, test, test' called attention and expectancy to these tools. Debate is ongoing amongst international public health agencies and national authorities to define the most reliable way to exploit Ag RDT [5; 11; 12]. As a matter of fact, how to incorporate Ag RDT in diagnostic algorithms and in public health strategies is the primary aspect to address in order to balance benefits and limitations of these tests.

Here, we describe the preliminary data from our experience in implementing Ag RDT at points-ofentry (PoE) in Rome, Italy, between 17 th of August to 15 th of October, 2020.

In August 2020, following the end of the national lockdown, the re-opening of borders and the intensification of citizen travels due to summer holidays, Italian authorities strengthened the border surveillance addressing all travelers returning from high incidence foreign countries, as well as from Sardinia region (Italy) [13] . On 17 th of August, in Lazio Region, on-site screening by SARS-CoV-2 Ag RDTs was implemented at the international airports in Rome ("Leonardo da Vinci International Airport", Fiumicino, and "Ciampino-G. B. Pastine International Airport", Ciampino), and at the port of Civitavecchia (Rome) for those ships returning from Sardinia region. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.26.20232728 doi: medRxiv preprint 4 The Ag RDTs used was the STANDARD F COVID-19 Ag Fluorescence ImmunoAssay (FIA, SD Biosensor, Korea). This test detects viral nucleoprotein (N) directly from nasopharyngeal swab (NPS); the interpretation of results is performed after 30 minutes incubation using an automatic fluorescence reader (STANDARD F100, SD Biosensor, Korea) which gives a cut-off index (COI) as measure of fluorescence signal detected in relation to the presence of viral antigen; COI ≥1 is interpreted as positive for SARS-CoV-2 N antigen. The antigenic testing was voluntary and the sample collection and Ag RDT execution was performed by trained health care workers deployed at the PoE (Regional Special Unit for Community Health Care, USCAR). Based on the sensitivity and specificity of this assay, established on a preliminary validation study [14] , assuming 1% prevalence, positive and negative predictive values (PPV and NPV) of this test were estimated to be 23.3% Virus culture was performed on selected RT-PCR confirmed samples, using Vero E6 cell line, as previously described [15] .

Results of each Ag RDT were recorded at the testing site through an electronic register and, subsequently, uploaded to the Regional Surveillance Information System established by the regional health authority. Anonymized data have been extracted and analyzed using STATA 14 statistical is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.26.20232728 doi: medRxiv preprint Spearman correlation test was performed using GraphPad Prism version 8.00 (GraphPad 160 Software, US). Positive Predictive value (PPV) and negative predictive value (NPV) were calculated using the MedCalc statistical software (MedCalc Software Ltd, Belgium).

This work was performed within the framework of the COVID-19 outbreak response and surveillance program, and has been approved by the INMI Ethical Committee ("Comitato Etico INMI Lazzaro Spallanzani IRCCS/Comitato Etico Unico Nazionale Covid-19"; issue n. 214/20-11-2020). All data are aggregated and non-identifiable.

From the 17 th of August to 15 th of October 2020, a total of 73,643 Ag RDT have been recorded in the The analysis was performed on a sub-set (n=603) of samples from subjects tested positive by Ag RDT with available COI values (Fig. 1) .

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.26.20232728 doi: medRxiv preprint Table   1 and Fig. 2 replication-competent virus was recovered from all of these samples, supporting the potential for SARS-CoV-2 transmission. In addition, a significant correlation (r = -0.6; p<0.0001) was observed between the Ct values, that are surrogate markers of viral load (lower Ct value corresponds to high viral load) and COI values resulted from the Ag RDT, which represent the extent of the antigen detection (Fig. 2) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.26.20232728 doi: medRxiv preprint Table 1 , the percentage of confirmed Ag RDT results was strongly dependent on the COI value, ranging from 81.6% when the COI threshold was set at 3 to 100% when the COI threshold was set at 20. More in details, positive Ag RDTs with COI≥10 were confirmed in 98.7% of cases with only 1.3% of Ag RDT false positive results, while lower cut-off showed higher percentage of Ag RDT false positivity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.26.20232728 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.26.20232728 doi: medRxiv preprint samples confirmed positive by NAAT. More importantly, our study shows that clinical samples resulted positive by Ag RDT and confirmed by NAAT harbor infectious virus. To our knowledge, this is the first report showing a linear correlation between viral loads in NPS (measured as Ct values) and extent of viral antigen detection (measured as COI values). As a consequence, the proportion of Ag RDT samples confirmed by a molecular test was extremely high (98.7%) in those samples with COI ≥10, reaching 100% with COI ≥20. This information may be of help for a reliable diagnostic interpretation of this specific tool and may be useful for a potential reassessment of the diagnostic algorithms of Ag RDT confirmation by NAAT. In fact, on the basis of the proportion of cases confirmed by NAAT according to their COI value, a threshold (e.g. COI≥10) may be established to exempt molecular testing when the expected confirmation rate exceeds 95%. Following this principle, it is possible that specific thresholds may be evaluated also for other semi-quantitative Ag RDT, prompting not only a consequent earlier implementation of public health measures, but also a potential advantage for the NAAT laboratory workload and demand in terms of staff effort and reagents supply, ultimately helping to relieve the pressure on healthcare systems [3-4; 11; 16].

A limitation of the present study is that Ag RDTs resulted negative at PoE did not undergo RT-PCR testing, so it was not possible to estimate the proportion of PCR-positive samples missed by Ag RDT.

However, in our opinion, though Ag RDTs are substantially less sensitive than NAAT [8], they are worth to be integrated into COVID-19 outbreak management programs, as they may contribute to the prompt isolation of highly infectious cases who would otherwise have been lost, highlighting the role of PoE testing as a pillar of outbreak control [11 ; 18] . In fact, the use of Ag RDT may be particularly advantageous to early minimize the risk of the virus spreading, especially when and where there is no immediate access to RT-PCR testing, or where this cannot be feasible, as for mass and frequent testing or in certain field settings. In addition, Ag RDT use could also represent a suitable screening tool for prompt cluster investigation and in specific cohorts such as asymptomatic contacts of COVID-19 confirmed cases, pauci-symptomatic patients with no epidemiological link and travelers with no symptoms [11] . Of course, public-awareness campaigns must also communicate that a negative Ag RDT does not necessarily implies a clean bill of health, and continued social distancing and mask wearing needs to be recommended. In addition, negative Ag RDT results in symptomatic patients should not be considered definitive, and molecular tests are required for a more reliable diagnostic assessment. Finally, it is necessary to balance clinical diagnostic performances of the tests, testing sustainability (i.e. cost, staff demand, technology and infrastructures, time to results), public health implications, and socio-economic consequences, which can also derive from delay in diagnostic response [3; 19]. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.26.20232728 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.26.20232728 doi: medRxiv preprint

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard

The Challenges of Expanding Rapid Tests to Curb COVID-19

Rethinking Covid-19 Test Sensitivity -A Strategy for Containment

Considerations for diagnostic COVID-19 tests

WHO Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: interim guidance

An alternative workflow for molecular detection of SARS-CoV-2 -escape from the NA extraction kit-shortage

Evaluation of rapid antigen test for detection of SARS-CoV-2 virus

Laboratory testing for the diagnosis of COVID-19

for the study team. Evaluation of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care diagnostics for SARS-CoV-2

Field Evaluation of the Performance of a SARS-CoV-2 Antigen Rapid Diagnostic Test in Uganda using Nasopharyngeal Samples

Test di laboratorio per SARS-CoV-2 e loro uso in sanità pubblica

Roma: Ministero della Salute, Istituto Superiore di Sanità

Interim Guidance for Rapid Antigen Testing for SARS-CoV-2

Disposizioni attuative del decreto-legge 25 marzo 2020, n. 19, recante misure urgenti per fronteggiare l'emergenza epidemiologica da COVID-19, e del decreto-legge 16 maggio 2020, n. 33, recante ulteriori misure urgenti per fronteggiare l'emergenza epidemiologica da COVID-19

Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples

Epub ahead of print

Virological characterization of the first two COVID-19 patients diagnosed in Italy: phylogenetic analysis, virus shedding profile from different body sites and antibody response kinetics. Open Forum Infect Dis

Urgent need of rapid tests for SARS CoV-2 antigen detection

Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples

World Health Organization. COVID-19 Strategic preparedness and response plan operational planning guidelines to support country preparedness and response. Geneva: WHO; 2020

Can we test our way out of the COVID-19 pandemic?

The authors declare no potential conflicts of interest. It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.26.20232728 doi: medRxiv preprint